1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fosun Pharma and Insilico Medicine Announces A Strategic, Ai-Driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

01/11/2022 | 03:30am EDT

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. This strategic collaboration includes an AI-driven drug discovery research and development (R&D) collaboration on four biological targets, as well as the co-development of Insilico's QPCTL program. Insilico will receive a total upfront payment of $13 million for the R&D collaboration projects and the co-development of the QPCTL program, potential milestone-based payments, and share commercialization profits from the QPCTL program. In addition, Fosun Pharma will make an equity investment in Insilico. The collaboration aims to combine Insilico's end-to-end AI-driven drug discovery platforms and Fosun Pharma's clinical development and commercial expertise to discover and develop a portfolio of novel therapeutics. Pursuant to the collaboration agreement, Insilico will take responsibility for delivering a preclinical candidate for the QPCTL program and advancing it to IND stage, after which, Fosun Pharma will then conduct human clinical studies and co-develop the candidate globally. In parallel, Fosun Pharma's R&D team will nominate four therapeutic targets to be assessed by Insilico's AI platform and R&D team, who are responsible of advancing drug candidates to IND stage.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION 0.70% 56.46 Delayed Quote.-16.87%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 1.62% 44.41 End-of-day quote.-9.26%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
05/19SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma and VerImmune enter into an Exclusive License..
PU
05/19Shanghai Fosun Pharmaceutical Co., Ltd. Recommends Final Dividend for 2021, Dispatch of..
CI
05/13Fosun Pharma Unit Gets Nod to Start Phase II Study in China of Hematologic Disorder Tre..
MT
05/11Chinese Shares Post Modest Gains; Gotion Jumps 4.5% on Argentina Deal
MT
05/11China’s Pharma Firms Post 67% Jump in Profit in 2021
MT
05/05Hangzhou Calibra Diagnostics Co., Ltd. announced that it has received CNY 220 million i..
CI
04/28SHANGHAI FOSUN PHARMACEUTICAL : Notification letter and request form to non-registered sha..
PU
04/28SHANGHAI FOSUN PHARMACEUTICAL : Form of proxy for holders of h shares for the 2022 first m..
PU
04/28SHANGHAI FOSUN PHARMACEUTICAL : Form of proxy for holders of h shares for the annual gener..
PU
04/28SHANGHAI FOSUN PHARMACEUTICAL : Notice of 2022 first h shareholders class meeting (h share..
PU
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2022 43 494 M 6 499 M 6 499 M
Net income 2022 5 095 M 761 M 761 M
Net Debt 2022 16 460 M 2 459 M 2 459 M
P/E ratio 2022 21,9x
Yield 2022 1,26%
Capitalization 105 B 15 699 M 15 699 M
EV / Sales 2022 2,79x
EV / Sales 2023 2,46x
Nbr of Employees 36 279
Free-Float 58,6%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 44,41 CNY
Average target price 55,27 CNY
Spread / Average Target 24,5%
EPS Revisions
Managers and Directors
Yi Fang Wu Chairman & Chief Executive Officer
Yu Qing Chen Co-President
Ke Xin Wang Vice Chairman & Co-President
Dong Ming Li Co-President
De Yong Wen Senior Vice President